title: Resveratrol supplementation: Where are we now and where should we go?
abstract: Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review, we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, toxicity of resveratrol, and resveratrol-drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combating diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments.
authors.affiliation: Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA; Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
authors.forename: Marta G
authors.initials: MG
authors.lastname: Novelle
authors.affiliation: Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
authors.forename: Devin
authors.initials: D
authors.lastname: Wahl
authors.affiliation: Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Diéguez
authors.affiliation: Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
authors.forename: Michel
authors.initials: M
authors.lastname: Bernier
authors.affiliation: Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA. Electronic address: decabora@grc.nia.nih.gov.
authors.forename: Rafael
authors.initials: R
authors.lastname: de Cabo
mesh_terms: D000375:Aging / Q000187:drug effects; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D019587:Dietary Supplements / Q000009:adverse effects; D015444:Exercise; D006801:Humans; D000077185:Resveratrol; D013267:Stilbenes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D000077185:Resveratrol
keywords: Bioavailability; Clinical trials; Metabolism; Resveratrol; Translational research